Compare · ALB vs CDXS
ALB vs CDXS
Side-by-side comparison of Albemarle Corporation (ALB) and Codexis Inc. (CDXS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALB and CDXS operate in Major Chemicals (Industrials), so they compete in similar markets.
- ALB is the larger of the two at $15.72B, about 85.4x CDXS ($184.0M).
- Both names hit the wire about 5 times in the past 4 weeks.
- ALB has more recent analyst coverage (25 ratings vs 12 for CDXS).
- Company
- Albemarle Corporation
- Codexis Inc.
- Price
- $133.25-5.90%
- $1.69+1.81%
- Market cap
- $15.72B
- $184.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Chemicals
- Major Chemicals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2010
- News (4w)
- 5
- 5
- Recent ratings
- 25
- 12
Albemarle Corporation
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Lithium, Bromine Specialties, and Catalysts. The Lithium segment offers lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and lithium specialties; and reagents, such as butyllithium and lithium aluminum hydride for use in lithium batteries for consumer electronics and electric vehicles, high performance greases, thermoplastic elastomers for car tires, rubber soles, plastic bottles, catalysts for chemical reactions, organic synthesis processes in the areas of steroid chemistry and vitamins, life sciences, pharmaceutical industry, and other markets. It also provides cesium products for the chemical and pharmaceutical industries; zirconium, barium, and titanium products for pyrotechnical applications; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services. The Bromine Specialties segment offers bromine and bromine-based fire safety solutions; specialty chemicals, including elemental bromine, alkyl and inorganic bromides, brominated powdered activated carbon, and other bromine fine chemicals for use in chemical synthesis, oil and gas well drilling and completion fluids, mercury control, water purification, beef and poultry processing, and other industrial applications; and other specialty chemicals, such as tertiary amines, biocides, disinfectants, and sanitizers. The Catalysts segment provides hydroprocessing, isomerization, and akylation catalysts; fluidized catalytic cracking catalysts and additives; and organometallics and curatives. The company serves the energy storage, petroleum refining, consumer electronics, construction, automotive, lubricants, pharmaceuticals, crop protection, and custom chemistry services markets. Albemarle Corporation was founded in 1887 and is headquartered in Charlotte, North Carolina.
Codexis Inc.
Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Latest ALB
- SEC Form 3 filed by new insider Hood Max
- Albemarle Corporation filed SEC Form 8-K: Leadership Update
- SEC Form 10-Q filed by Albemarle Corporation
- Albemarle Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Albemarle Reports Second Quarter 2026 Results
- Director Desalles Bartolomeo Eduardo was granted 1,375 shares (SEC Form 4)
- SEC Form 3 filed by new insider Desalles Bartolomeo Eduardo
- Albemarle Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Albemarle Appoints Eduardo Bartolomeo to Board of Directors
- Albemarle Announces Quarterly Common Stock Dividend
Latest CDXS
- Amendment: SEC Form SCHEDULE 13G/A filed by Codexis Inc.
- SEC Form 10-Q filed by Codexis Inc.
- Codexis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Codexis Reports Second Quarter 2026 Financial Results
- Codexis Appoints David Butler, PhD, to Strategic Advisory Board
- Codexis to Report Second Quarter 2026 Financial Results on August 11
- SEC Form 8-K filed by Codexis Inc.
- SEC Form 424B5 filed by Codexis Inc.
- Codexis Announces Pricing of Public Offering of Common Stock
- SEC Form 424B5 filed by Codexis Inc.